Tags

Type your tag names separated by a space and hit enter

Long term population impact of seven-valent pneumococcal conjugate vaccine with a "3+0″ schedule-How do "2+1″ and "3+1″ schedules compare?
Vaccine. 2015 Jun 22; 33(28):3234-41.V

Abstract

INTRODUCTION

Significant reductions in invasive pneumococcal disease (IPD) following 7-valent pneumococcal conjugate vaccine (7vPCV) are well documented, but population-level data comparing different schedules are sparse. We compared data from long-term stable surveillance in one Australian region (3 primary doses (3+0) schedule) with similar data from England and Wales (2+1 schedule) and the United States (3+1 schedule).

METHODS

Incidence rate ratios (IRRs) for all, vaccine type, and non-vaccine type IPD were calculated by age-group, using comparable case definitions and time periods post 7vPCV introduction.

RESULTS

At baseline, the % of IPD due to 7vPCV serotypes (VT) disease in children <5 years was 88% in Greater Sydney (GS), 83% in the United States (US), and 74% in England and Wales (E&W). IRR for VT IPD <5 years in GS was 0.05 (0.02-0.09), for ≥65 years was 0.15 (0.12-0.19) and for all ages 0.12 (0.10-0.13). In the US, IRR for VT IPD was lower in each age group, and for all ages the 95% CI of the IRR (0.06 (0.05-0.07)), did not overlap with GS or E&W (0.14 (0.11-0.18)). In contrast, the IRR for IPD due to any serotype did not differ between sites for any age group or overall.

CONCLUSIONS

Differences in direct and indirect reductions in VT IPD with a "3+0″ 7vPCV schedule versus "2+1″ or "3+1″ were small. All 3 countries moved to 13vPCV by 2011; data post 13vPCV will be important to assess IPD impact using more similar baseline incidence and comparison periods.

Authors+Show Affiliations

Public Health Officer Training Program, New South Wales Ministry of Health, Sydney, NSW, Australia; School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia. Electronic address: clowb@doh.health.nsw.gov.au.National Centre for Immunisation Research and Surveillance, Children's Hospital, Westmead, Sydney, NSW, Australia; Discipline of Paediatrics and Child Health and School of Public Health, University of Sydney, Children's Hospital, Westmead, Sydney, NSW, Australia. Electronic address: peter.mcintyre@health.nsw.gov.au.Health Protection New South Wales, Sydney, Australia. Electronic address: rgilm@doh.health.nsw.gov.au.National Centre for Immunisation Research and Surveillance, Children's Hospital, Westmead, Sydney, NSW, Australia. Electronic address: clayton.chiu@health.nsw.gov.au.School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia. Electronic address: h.seale@unsw.edu.au.School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia. Electronic address: mark.ferson@sesiahs.health.nsw.gov.au.Centre for Infectious Diseases and Microbiology-Public Health, Sydney, NSW, Australia. Electronic address: lyn.gilbert@sydney.edu.au.

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25952557

Citation

Lowbridge, Christopher, et al. "Long Term Population Impact of Seven-valent Pneumococcal Conjugate Vaccine With a "3+0″ schedule-How Do "2+1″ and "3+1″ Schedules Compare?" Vaccine, vol. 33, no. 28, 2015, pp. 3234-41.
Lowbridge C, McIntyre PB, Gilmour R, et al. Long term population impact of seven-valent pneumococcal conjugate vaccine with a "3+0″ schedule-How do "2+1″ and "3+1″ schedules compare? Vaccine. 2015;33(28):3234-41.
Lowbridge, C., McIntyre, P. B., Gilmour, R., Chiu, C., Seale, H., Ferson, M. J., & Gilbert, G. L. (2015). Long term population impact of seven-valent pneumococcal conjugate vaccine with a "3+0″ schedule-How do "2+1″ and "3+1″ schedules compare? Vaccine, 33(28), 3234-41. https://doi.org/10.1016/j.vaccine.2015.04.079
Lowbridge C, et al. Long Term Population Impact of Seven-valent Pneumococcal Conjugate Vaccine With a "3+0″ schedule-How Do "2+1″ and "3+1″ Schedules Compare. Vaccine. 2015 Jun 22;33(28):3234-41. PubMed PMID: 25952557.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long term population impact of seven-valent pneumococcal conjugate vaccine with a "3+0″ schedule-How do "2+1″ and "3+1″ schedules compare? AU - Lowbridge,Christopher, AU - McIntyre,Peter B, AU - Gilmour,Robin, AU - Chiu,Clayton, AU - Seale,Holly, AU - Ferson,Mark J, AU - Gilbert,Gwendolyn L, Y1 - 2015/05/05/ PY - 2014/10/17/received PY - 2015/04/01/revised PY - 2015/04/22/accepted PY - 2015/5/9/entrez PY - 2015/5/9/pubmed PY - 2016/3/16/medline KW - Comparison KW - Conjugate KW - Pneumococcal KW - Schedule KW - Vaccination SP - 3234 EP - 41 JF - Vaccine JO - Vaccine VL - 33 IS - 28 N2 - INTRODUCTION: Significant reductions in invasive pneumococcal disease (IPD) following 7-valent pneumococcal conjugate vaccine (7vPCV) are well documented, but population-level data comparing different schedules are sparse. We compared data from long-term stable surveillance in one Australian region (3 primary doses (3+0) schedule) with similar data from England and Wales (2+1 schedule) and the United States (3+1 schedule). METHODS: Incidence rate ratios (IRRs) for all, vaccine type, and non-vaccine type IPD were calculated by age-group, using comparable case definitions and time periods post 7vPCV introduction. RESULTS: At baseline, the % of IPD due to 7vPCV serotypes (VT) disease in children <5 years was 88% in Greater Sydney (GS), 83% in the United States (US), and 74% in England and Wales (E&W). IRR for VT IPD <5 years in GS was 0.05 (0.02-0.09), for ≥65 years was 0.15 (0.12-0.19) and for all ages 0.12 (0.10-0.13). In the US, IRR for VT IPD was lower in each age group, and for all ages the 95% CI of the IRR (0.06 (0.05-0.07)), did not overlap with GS or E&W (0.14 (0.11-0.18)). In contrast, the IRR for IPD due to any serotype did not differ between sites for any age group or overall. CONCLUSIONS: Differences in direct and indirect reductions in VT IPD with a "3+0″ 7vPCV schedule versus "2+1″ or "3+1″ were small. All 3 countries moved to 13vPCV by 2011; data post 13vPCV will be important to assess IPD impact using more similar baseline incidence and comparison periods. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/25952557/Long_term_population_impact_of_seven_valent_pneumococcal_conjugate_vaccine_with_a_"3+0″_schedule_How_do_"2+1″_and_"3+1″_schedules_compare L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(15)00565-4 DB - PRIME DP - Unbound Medicine ER -